Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
toripalimab + nab-paclitaxel + oxaliplatin + fluorouracil + leucovorin
- Development stage
- Phase 2
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Toripalimab (JS001) is a humanized IgG4 monoclonal antibody developed by Shanghai Junshi Biosciences that targets the programmed cell death protein 1 (PD-1) receptor. As an immune checkpoint inhibitor, it blocks the interaction between PD-1 and its ligands (PD-L1 and PD-L2), thereby restoring the anti-tumor activity of T cells. In a specific Phase II clinical trial sponsored by Wan He, toripalimab is being evaluated as a perioperative treatment in combination with the FLOAP chemotherapy regimen. The FLOAP regimen consists of nanoparticle albumin-bound (nab) paclitaxel, oxaliplatin, fluorouracil (5-FU), and leucovorin. This combination therapy is being investigated for patients with locally advanced gastric cancer and gastroesophageal junction (GEJ) adenocarcinoma, with the primary objective of increasing the pathological complete response (pCR) rate and improving long-term survival outcomes.
- Brand names
- Tuoyi
- Other names
- toripalimab + FLOAP
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on toripalimab + nab-paclitaxel + oxaliplatin + fluorouracil + leucovorin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on toripalimab + nab-paclitaxel + oxaliplatin + fluorouracil + leucovorin.